3,306
Views
39
CrossRef citations to date
0
Altmetric
Research Article

Liver-targeted delivery of insulin-loaded nanoparticles via enterohepatic circulation of bile acids

, , &
Pages 1224-1233 | Received 12 Feb 2018, Accepted 16 Apr 2018, Published online: 23 May 2018

References

  • Alam F, Al-Hilal TA, Chung SW, et al. (2014). Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials 35:6543–52.
  • Arbit E. (2004). The physiological rationale for oral insulin administration. Diabetes Technol 6:510–7.
  • Chuang EY, Lin KJ, Lin PY, et al. (2015). Self-assembling bubble carriers for oral protein delivery. Biomaterials 64:115–24.
  • Du H, Liu M, Yang X, Zhai G. (2015). The design of pH-sensitive chitosan-based formulations for gastrointestinal delivery. Drug Discov Today 20:1004–11.
  • Edgerton DS, Lautz M, Scott M, et al. (2006). Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 116:521–7.
  • Fan W, Xia D, Zhu Q, et al. (2018). Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials 151:13–23.
  • Geho WB, Geho HC, Lau JR, Gana TJ. (2009). Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J Diabetes Sci Technol 3:1451–9.
  • Gong YZ, Everett ET, Schwartz DA, et al. (1994). Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. Proc Natl Acad Sci 91:4741–5.
  • Ho NFH. (1987). Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann N Y Acad Sci 507:315–29.
  • Hsu LW, Ho YC, Chuang EY, et al. (2013). Effects of pH on molecular mechanisms of chitosan-integrin interactions and resulting tight-junction disruptions. Biomaterials 34:784–93.
  • IDF Diabetes Atalas. (2017). International Diabetes Federation, Available at: http://www.idf.org/diabetesatlas.
  • Khatun Z, Nurunnabi, Cho KJ, et al. (2014). Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. J Control Release 177:64–73.
  • Kolhatkar V, Polli JE. (2012). Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. Eur J Pharm Sci 46:86–99.
  • Li Z, Hu X, Jiang J, et al. (2018). Recent advances in closed-loop and smart insulin delivery systems. Chin J Org Chem 38:29–39.
  • Lopes MA, Abrahim BA, Seiça R, et al. (2014). Intestinal uptake of insulin nanoparticles: facts or myths? Curr Pharm Biotechnol 15:629–38.
  • Makhlof A, Tozuka Y, Takeuchi H. (2011). Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci 42:445–51.
  • Mcginn BJ, Morrison JD. (2016). Investigations into the absorption of insulin and insulin derivatives from the small intestine of the anaesthetised rat. J Control Release 232:120–30.
  • Mo R, Jiang T, Di J, et al. (2014). Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev 43:3595–629.
  • Pessin JE, Saltiel AR. (2000). Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165–9.
  • Saltiel AR, Kahn CR. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806.
  • Schadt HS, Wolf A, Pognan F, et al. (2016). Bile acids in drug induced liver injury: key players and surrogate markers. Clin Res Hepatol Gastroenterol 40:257–66.
  • Sheng J, He H, Han L, et al. (2016). Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates. J Control Release 233:181–90.
  • Singh B, Maharjan S, Jiang T, et al. (2015). Attuning hydroxypropyl methylcellulose phthalate to oral delivery vehicle for effective and selective delivery of protein vaccine in ileum. Biomaterials 59:144–59.
  • Swaan PW, Szoka FC, Øie S. (1996). Use of the intestinal and hepatic bile acid transporters for drug delivery. Adv Drug Deliv Rev 20:59–82.
  • Wang X, Shi C, Zhang L, et al. (2016). Affinity-controlled protein encapsulation into sub-30 nm telodendrimer nanocarriers by multivalent and synergistic interactions. Biomaterials 101:258–71.
  • Zambito Y, Felice F, Fabiano A, et al. (2013). Mucoadhesive nanoparticles made of thiolated quaternary chitosan crosslinked with hyaluronan. Carbohydr Polym 92:33–9.
  • Zhang D, Li D, Shang L, et al. (2016a). Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption. Int J Pharm 511:161–9.
  • Zhang Z, Cai H, Liu Z, Yao P. (2016b). Effective enhancement of hypoglycemic effect of insulin by liver-targeted nanoparticles containing cholic acid-modified chitosan derivative. Mol Pharm 13:2433–42.